Evidence map›Paper›PMID 41671552›Full record

ArticleJMIR cancer2026

The Longevity of Mobile Apps for Cancer Recovery: Scoping Review.

Kenneth Färnqvist, Luisa Thiele, Sophie Johnsson, Pernilla Lagergren, Anna Schandl

Abstract readScoping Review
In one paragraph

Article in JMIR cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kenneth Färnqvist *Department of Molecular Medicine and Surgery, Karolinska Institute, Blombäcksväg 23, Stockholm, 171 77, Sweden, 46 733615317.ORCID 0000-0002-3529-565X
Luisa Thiele *Department of Molecular Medicine and Surgery, Karolinska Institute, Blombäcksväg 23, Stockholm, 171 77, Sweden, 46 733615317.ORCID 0009-0005-6789-0428
Sophie JohnssonDepartment of Molecular Medicine and Surgery, Karolinska Institute, Blombäcksväg 23, Stockholm, 171 77, Sweden, 46 733615317.ORCID 0000-0002-9383-1465
Pernilla LagergrenDepartment of Molecular Medicine and Surgery, Karolinska Institute, Blombäcksväg 23, Stockholm, 171 77, Sweden, 46 733615317.ORCID 0000-0002-4634-0233
Anna SchandlDepartment of Molecular Medicine and Surgery, Karolinska Institute, Blombäcksväg 23, Stockholm, 171 77, Sweden, 46 733615317.ORCID 0000-0002-3603-1912

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The number of cancer survivors is steadily increasing worldwide, leading to an increased demand for long-term follow-up and supportive care. Many survivors face ongoing physical and psychosocial issues that highlight the need for innovative management approaches. Mobile health apps offer potential benefits by facilitating patient-led follow-up, self-management, and more efficient use of health care resources. Although the market for cancer-related mobile apps has grown rapidly, their sustainability and scientific basis remain unclear. In the European Union, the Medical Device Regulation (MDR), in effect since May 2021, introduced stricter criteria for classifying medical devices, including certain software apps. While aiming to improve patient safety, the MDR could pose challenges for small companies and academic developers, potentially limiting the availability of such apps. No scoping review has delineated changes in active apps before and after implementation of the legislation regulating medical devices. Objective: This scoping review aimed to evaluate the current availability and longevity of English-language mobile apps supporting cancer recovery, with a specific focus on changes before and after the implementation of the European Union MDR, and to assess the extent to which these apps are supported by clinical evidence. Methods: Searches were conducted in mobile app stores (Apple's App Store and Google Play) and literature databases (MEDLINE, Embase, Cochrane Library, and Web of Science), using predefined terms. Mobile apps targeting cancer recovery and published articles on their effectiveness were included. Two reviewers independently extracted data. A descriptive analysis was conducted to report trends in mobile device app availability and updates over time. Results: A total of 151 mobile apps were identified in 2018. However, by 2024, only 45 of 151 (30%) were still available. Among these, 25 of 151 (17%) were updated within the past 2 years. During the search in December 2024, 1 new mobile app supported by scientific evidence was discovered. This mobile app was developed to assist cancer survivors in managing insomnia through cognitive behavioral therapy. Rapid turnover and a potential lack of sustainability in the mobile health app market for cancer survivors were evident, with most mobile apps identified in 2018 no longer available by 2024. Conclusions: This review revealed a limited number of publicly available mobile apps that support cancer recovery. The longevity of existing mobile apps is limited, potentially because of regulatory and financial barriers. Prioritizing rigorous effectiveness trials, addressing implementation barriers, and developing sustainable business models are essential to ensure the long-term availability and success of mobile health apps in cancer survivorship care.

Indexed as

Cancer SurvivorsMobile ApplicationsNeoplasmsHumansTelemedicinecancercancer survivorshipmobile healthneoplasmsymptoms

Identifiers

PMID41671552
PMCPMC12893644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.